CN108852927A - 一种含生长因子的祛痘除印护肤组合物及其应用 - Google Patents
一种含生长因子的祛痘除印护肤组合物及其应用 Download PDFInfo
- Publication number
- CN108852927A CN108852927A CN201810658873.XA CN201810658873A CN108852927A CN 108852927 A CN108852927 A CN 108852927A CN 201810658873 A CN201810658873 A CN 201810658873A CN 108852927 A CN108852927 A CN 108852927A
- Authority
- CN
- China
- Prior art keywords
- pox
- skin care
- care compositions
- growth factor
- dispelling function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 239000003102 growth factor Substances 0.000 title claims abstract description 21
- 229910003472 fullerene Inorganic materials 0.000 claims abstract description 27
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 24
- 230000003255 anti-acne Effects 0.000 claims abstract description 20
- 244000179970 Monarda didyma Species 0.000 claims abstract description 11
- 235000010672 Monarda didyma Nutrition 0.000 claims abstract description 11
- 229940023555 leucojum aestivum bulb extract Drugs 0.000 claims abstract description 10
- 240000001548 Camellia japonica Species 0.000 claims abstract description 8
- 235000018597 common camellia Nutrition 0.000 claims abstract description 8
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 claims abstract description 5
- 229940116978 human epidermal growth factor Drugs 0.000 claims abstract description 5
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 claims abstract description 5
- 229920000288 Keratan sulfate Polymers 0.000 claims description 24
- -1 sulfuric acid Keratan oligosaccharide Chemical class 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 14
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 6
- 229920001542 oligosaccharide Polymers 0.000 claims description 6
- 230000006798 recombination Effects 0.000 claims description 6
- 238000005215 recombination Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 229960003067 cystine Drugs 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 68
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 37
- 206010000496 acne Diseases 0.000 abstract description 37
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 4
- 230000028327 secretion Effects 0.000 abstract description 4
- 210000001519 tissue Anatomy 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 239000004519 grease Substances 0.000 abstract description 3
- 210000003780 hair follicle Anatomy 0.000 abstract description 3
- 238000004090 dissolution Methods 0.000 abstract description 2
- 230000009707 neogenesis Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 25
- 238000012360 testing method Methods 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 241000186427 Cutibacterium acnes Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004909 Moisturizer Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- 229940055019 propionibacterium acne Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- XTURYZYJYQRJDO-BNAHBJSTSA-N Acetyl-farnesyl-cysteine Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@@H](C(O)=O)NC(C)=O XTURYZYJYQRJDO-BNAHBJSTSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 244000223141 Leucojum aestivum Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000036252 glycation Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- 241000282470 Canis latrans Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 240000007126 Citrus medica var. sarcodactylis Species 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 208000036828 Device occlusion Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 240000003537 Ficus benghalensis Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 description 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 description 1
- 102000002268 Hexosaminidases Human genes 0.000 description 1
- 108010000540 Hexosaminidases Proteins 0.000 description 1
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 1
- 241000972672 Phellodendron Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 241000863032 Trieres Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000009186 Vitex agnus castus extract Substances 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000037310 combination skin Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000044072 human ANGPT1 Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种含生长因子的祛痘除印护肤组合物及其应用。所述的祛痘除印护肤组合物包括以下组分:重组人表皮生长因子、水溶性富勒烯、ArazineTM、夏雪片莲鳞茎提取物、佛手柑提取物和山茶花提取物。本发明提供的祛痘除印护肤组合物各成分搭配合理,配比科学,协同的发挥消炎抑菌,调节油脂分泌,有效溶解油脂,疏通堵塞毛囊,促进细胞新生和修复重建组织,从而达到祛痘、消除痘印的目的。
Description
技术领域
本发明属于化妆品技术领域,具体涉及一种含生长因子的祛痘除印护肤组合物及其应用。
背景技术
青春痘,又名为痤疮,是毛囊皮脂腺的一种慢性炎症性皮肤病,临床表现为好发于面部的粉刺、丘疹、脓疱、结节等多形性皮损,不仅对生理健康有影响,而且对人的心理和社交影响很大,且大多数痘痘都会留下痘印,如果不及时治疗会留下永久性痘印,更加影响美观。
现代医学认为,青春痘的发生主要与皮脂分泌过多、毛囊皮脂腺导管堵塞、细菌感染和炎症反应等因素密切相关。进入青春期后人体内雄激素特别是睾酮的水平迅速升高,促进皮脂腺发育并产生大量皮脂。同时毛囊皮脂腺导管的角化异常造成导管堵塞,皮脂排出障碍,形成角质栓即微粉刺。毛囊中多种微生物尤其是痤疮丙酸杆菌大量繁殖,痤疮丙酸杆菌产生的脂酶分解皮脂生成游离脂肪酸,同时趋化炎症细胞和介质,最终诱导并加重炎症反应。青春痘严重影响人的容貌和自信,对人们的工作、生活产生消极影响,因此祛痘是化妆品的研究焦点之一。
为了提高祛痘化妆品的祛痘功效,研究者积极寻求各种祛痘活性物质。目前市面上的祛痘产品主要存在以下问题:1)对皮肤刺激性大,易引起皮肤过敏;2)加入的祛痘抑菌剂破坏皮肤的正常菌落;3)加入禁用激素,造成依赖。如何针对粉刺皮肤的生理病理特征,研发出高效又安全的祛痘类化妆品是研究者有待努力的方向。公开号为CN 103961283 A的中国专利申请公开了一种祛痘修复冻干制剂,该制剂包含有LS9088、黄柏提取物、水解印榕仙人掌花提取物、穗花牡荆提取物、小分子量透明质酸、人源抗菌肽、重组人角质细胞生长因子、重组人酸性成纤维细胞生长因子、重组人血管生成素-1、重组人白介素-1受体拮抗剂、含锌金属硫蛋白、重组人血小板衍生生长因子、植物甘草提取精华、透明质酸和维生素E醋脂酸等十多种有效成分,不仅有传统原料的祛痘消痈作用,还具有杀菌修复功效,使青春痘更容易去除并且不易再复发,但成本相对较高。
发明内容
本发明的目的是提供一种含生长因子的祛痘除印护肤组合物及其应用,所述的祛痘除印护肤组合物各成分之间协同效果佳,可有效祛痘、抚平痘坑,淡化痘印,实现祛痘效果持久不反复。
本发明是通过以下技术方案予以实现的:
一种含生长因子的祛痘除印护肤组合物,包括以下重量份的组分:重组人表皮生长因子0.00005~0.001份、水溶性富勒烯3~9份、N-乙酰基-S-法呢基-L-半胱氨酸0.5~3份、夏雪片莲鳞茎提取物1~4份和佛手柑提取物1~4份。
优选地,所述的含生长因子的祛痘除印护肤组合物,还包括以下重量份的组分:山茶花提取物1~6份。
优选地,所述的含生长因子的祛痘除印护肤组合物,包括以下重量份的组分:重组人表皮生长因子0.0001~0.001份、水溶性富勒烯3~6份、N-乙酰基-S-法呢基-L-半胱氨酸1~2份、夏雪片莲鳞茎提取物1~3份、佛手柑提取物1~2份和山茶花提取物2~4份。
优选地,所述的含生长因子的祛痘除印护肤组合物,包括以下重量份的组分:重组人表皮生长因子0.0005份、水溶性富勒烯6份、N-乙酰基-S-法呢基-L-半胱氨酸2份、夏雪片莲鳞茎提取物2份、佛手柑提取物2份和山茶花提取物3份。
进一步地,所述的水溶性富勒烯为硫酸角质素寡聚糖-富勒烯C60复合物,所述的水溶性富勒烯中富勒烯C60所占的质量百分比为4~8%。
进一步地,所述的硫酸角质素寡聚糖选自硫酸角质素二糖和硫酸角质素三糖中的至少一种。所述的硫酸角质素寡聚糖可以为市售产品,也可以为自制产品,其制备方法参考公开号为CN 1174557A的中国专利申请“硫酸角质素寡聚糖级分及含该级分的药剂”,具体为:取硫酸角质素50g,溶解在300ml的0.1M醋酸缓冲液(pH6.0)中,加入25U内-β-N-乙酰基葡萄糖胺酶型硫酸降解酶,在37℃下降解24h。反应结束后,加入2倍体积的乙醇,搅拌,在室温下放置1夜,在4000rpm下离心15min,取上清(上清A)。往沉淀中加入300ml蒸馏水,进行溶解,加入3倍量的乙醇,搅拌,在室温下放置1夜,4000rpm下离心15min,取上清(上清B)。将上清A和上清B混合,减压浓缩,使用Bio-Gel-P-2柱(3.6╳134cm),以蒸馏水作为溶剂,进行凝胶过滤,冷冻干燥,最后将制得的冻干粉采用离子交换色谱进行分离,分别收集硫酸角质素二糖、硫酸角质素三糖的级分,干燥,即得。
进一步地,本发明还提供一种所述的水溶性富勒烯的制备方法,包括以下步骤:
(1)将硫酸角质素寡聚糖和富勒烯C60粉末按重量比为1:20~30混合均匀,以600~800r/min研磨2~3h,加入双蒸水,置于恒温振荡器,在35~37℃,转速100r/min条件下振荡30min,得混悬液;
(2)将混悬液置于超声水浴锅中,在超声频率为20~30kHz,温度为60℃条件下处理60min,然后采用0.45μm的滤膜进行过滤,将滤液浓缩干燥,即得水溶性富勒烯。
本发明提供的含生长因子的祛痘除印护肤组合物可用于制备祛痘除印护肤品;所述的祛痘除印护肤品包含但不限于爽肤水、乳液、面霜、面膜或精华液。
本发明提供的祛痘除印护肤组合物中,ArazineTM(N-acetyl-S-farnesyl-L-cysteine,N-乙酰基-S-法呢基-L-半胱氨酸,CAS号:135304-07-3)是一种抗炎性的抗氧化剂,可用于对痘的消炎,因此,发明人将其应用于祛痘类护肤品中,但是发现其实际使用的祛痘效果不明显。为此,发明人通过大量的试验发现,以重组人表皮生长因子、水溶性富勒烯、ArazineTM、夏雪片莲鳞茎提取物和佛手柑提取物复配作为主要活性成分,起到优良的祛痘功效,并能调理皮肤,抚平痘坑,淡化痘印。其中,水溶性富勒烯具有较佳的抑菌、控油、软化角质作用,可控制皮肤过多的油脂分泌,剥落表皮死亡组织,打开毛孔通道;佛手柑提取物具有较佳的抑菌消炎作用,可有效杀灭痤疮丙酸杆菌、螨虫等皮肤寄生菌群,防止细菌原体浸蚀而发炎长痘;夏雪片莲鳞茎提取物可休眠黑色素细胞,减少黑色素的生成,促进痘痕的消除,并可减少皱纹,平滑肌肤,促进痘坑抚平;重组人表皮生长因子能够可改善皮肤微循环,改变皮肤各种细胞组织的代谢,有效恢复皮下结缔组织的生长,从而使皮肤光滑细嫩,富有弹性,消除痘印。以上各成分之间相互作用,可快速渗入肌肤,达到安全高效的祛痘、消除痘印、修复肌肤的目的。进一步添加山茶花提取物,由于其富含茶多酚和维生素B1、B2,具有显著的抗氧化、抗菌消炎、调节血流量的作用,富含的茶多酚对5-α还原酶具有显著的抑制作用,可调节激素水平,抑制皮脂腺的分泌,富含的维生素B1和B2是细胞生物氧化和能量代谢的辅酶,可促进发育和细胞再生,可获得更加佳的祛痘、消除痘印效果,实现祛痘效果持久不反复。
另外,本发明人在研究中发现,由于硫酸角质素寡聚糖-富勒烯C60复合物引入了分子量相对较小的硫酸角质素二糖和/或硫酸角质素三糖,并且相对于富勒烯C60,硫酸角质素二糖和/或硫酸角质素三糖的含量较高,长期使用,存在一定引起肌肤糖化作用的风险,使暗沉老化,痘印不宜消除,本发明通过大量的研究发现,通过加入一定量的夏雪片莲鳞茎提取物和佛手柑提取物,可有效抑制糖化反应的产生,所述的佛手柑提取物富含橙皮苷,可有效抑制蛋白糖化终末产物的生成;所述的夏雪片莲鳞茎提取物可增强溶酶体的活性,促进降解受损的蛋白质,两者相互作用,有效防止糖化终产物的形成,降低硫酸角质素二糖、硫酸角质素三糖的肌肤糖化风险,并抑制肌肤本身含有的游离糖的糖化作用,从而充分发挥消除痘印、抚平痘坑的效果。
与现有技术相比,本发明具有以下有益效果:
(1)本发明提供的祛痘除印护肤组合物各成分搭配合理,配比科学,协同的发挥消炎抑菌,调节油脂分泌,有效溶解油脂,疏通堵塞毛囊,促进细胞新生和修复重建组织,从而达到祛痘、消除痘痕的目的。
(2)本发明提供的祛痘除印护肤组合物性质温和,没有毒副作用,对皮肤具有一定的调理作用,可有效抑制肌肤的糖化作用,延缓皮肤老化,具有较佳的保湿效果和抗氧化效果,可淡化色斑。
具体实施方式
以下实施例是对本发明的进一步说明,而不是对本发明的限制。下述实施例中配方的组分,若无特别说明,均为常规市售产品,其中,水解大米蛋白(Prolixir ICE)购自美国亚什兰集团Ashland;夏雪片莲鳞茎提取物(IBR-)购自以色列IBR公司、佛手柑提取物和山茶花提取物购自美国艾缇科技公司(Active Concepts)。
实施例1水溶性富勒烯的制备
(1)称取10g硫酸角质素二糖和500mg富勒烯C60粉末,混合均匀,以600r/min研磨3h,加入双蒸水,置于恒温振荡器,在35℃,转速100r/min条件下振荡30min,得混悬液;
(2)将混悬液置于超声水浴锅中,在超声频率为30kHz,温度为60℃条件下处理60min,然后采用0.45μm的滤膜进行过滤,将滤液浓缩干燥,即得硫酸角质素二糖-富勒烯C60复合物,所述的复合物中富勒烯C60所占的质量百分比为8%。
实施例2水溶性富勒烯的制备
(1)称取10g硫酸角质素三糖和200mg富勒烯C60粉末,混合均匀,以800r/min研磨2h,加入双蒸水,置于恒温振荡器,在37℃,转速100r/min条件下振荡30min,得混悬液;
(2)将混悬液置于超声水浴锅中,在超声频率为20kHz,温度为60℃条件下处理60min,然后采用0.45μm的滤膜进行过滤,将滤液浓缩干燥,即得硫酸角质素三糖-富勒烯C60复合物,所述的复合物中富勒烯C60所占的质量百分比为4%。
实施例3-6和对比例1-5祛痘除印护肤组合物的制备
实施例3-6和对比例1-5祛痘除印护肤组合物的制备包括以下重量份的组分:
制备方法:按上表所示的重量份,分别称取配方各组分原料,混合均匀,即得祛痘除印护肤组合物。
含实施例3祛痘除印护肤组合物的祛痘膏制备:
(1)配方:
余量为去离子水。
(2)制备方法:
S1:将鲸蜡硬脂醇醚-6、棕榈酸乙基己酯、辛酸甘油三酯、聚二甲基硅氧烷置于油相锅中,加热至80℃,搅拌至完全溶解,得到物料A,保温备用;
S2:将水、聚甘油-10、羧甲基脱乙酰壳聚糖、黄原胶加入水相锅中,加热至80℃,搅拌至完全溶解后抽入已预热的均质乳化锅中,开启搅拌,再将物料A缓慢抽入乳化锅中,均质10min后降温;
S3:继续降温至35℃,加入乙基己基甘油、实施例3祛痘除印护肤组合物,搅拌均匀,抽样检测,合格后出料制得含实施例3祛痘除印护肤组合物的祛痘膏。
含实施例4-6和对比例1-5的祛痘除印护肤组合物的祛痘膏制备参考上述所示,各试验例中对应的祛痘除印护肤组合物的加入量均为10wt%。
含实施例3祛痘除印护肤组合物的护肤液制备:
(1)配方:
余量为去离子水。
(2)制备方法:将实施例3祛痘除印护肤组合物、甘油、丙二醇、苯氧乙醇加入到去离子水中,搅拌至物料完全溶解,分装,即得护肤液。
含实施例4-6和对比例1-5的祛痘除印护肤组合物的护肤液制备参考上述所示,各试验例中对应的祛痘除印护肤组合物的加入量均为8wt%。
试验例一、皮肤刺激性试验
选择180名受试志愿者作为实验对象,分为9组,分别为实施例3-6组、对比例1-5组,每组20名,对应给予含本发明实施例3-6、对比例1-5祛痘除印护肤组合物的祛痘膏。取0.1g样品置于斑试胶带的药室内,立即将置有样品的斑试胶带从下部开始纵向贴于左前臂的正常皮肤上,同时逐个轻压药室以驱除空气,并使试验物均匀分布。试验部位做好标记,以便观察。每隔24小时贴肤一次,揭开贴片后半小时,按照CTFA指南的术语进行检查,共进行6次斑贴试验,贴肤结束后的第6天,为了观察迟发反应,进行了追加检查。对最后一次检查的结果进行比较,鉴定标准见表1,结果见表2。
表1鉴定标准
等级 | 符号 | 鉴定标准 |
0 | - | 阴性反应;无刺激、无红斑 |
1 | ± | 可疑反应:轻度红斑 |
2 | + | 弱阳性反应:红斑 |
3 | ++ | 强阳性反应:红斑、丘疹、水疱 |
4 | +++ | 极强阳性反应:严重浮肿、大泡 |
表2皮肤刺激性试验结果
结果显示,含本发明实施例3-6和对比例1-5祛痘除印护肤组合物的祛痘膏均无阳性反应出现,皮肤刺激性等级为0级,说明本发明提供的祛痘除印护肤组合物对皮肤无刺激,产品安全、温和。
试验例二、抑菌试验
参照GB 15979-2002《一次性使用卫生用品卫生标准》中附录C 4“溶出性抗(抑)菌产品抑菌性能试验方法”验证含本发明提供的祛痘除印护肤组合物的祛痘膏是否对引发痘痘的直接微生物具有抑制作用,结果见表3。
表3抑菌效果评价结果
结果显示,含本发明祛痘除印护肤组合物的祛痘膏对青春痘相关菌种如:颗粒丙酸杆菌、痤疮丙酸杆菌、表皮葡萄球菌和金黄色葡萄球菌均具有较佳的杀菌抑制效果,各成分之间协同效果佳,尤其以实施例6的效果最佳。
试验例三、控油效果试验
选择180名男性受试志愿者作为实验对象,均为油性及混合性肌肤,无任何皮肤病及皮肤过敏史,分为9组,分别为实施例3-6组、对比例1-5组,每组20名,对应给予含本发明实施例3-6、对比例1-5祛痘除印护肤组合物的祛痘膏。受试志愿者每天早晚使用一次测试样品,连续使用4周。在使用前和使用4周后分别采用皮肤油脂测试探头(Sebumeter,德国CK),根据世界公认的油份测试SEBUMETER法,对受试志愿者的皮肤油脂含量进行测试,测试时,使用皮肤油脂测试探头测试额头部位3次,取平均值,实验结果见表4。
表4控油效果评价结果
组别 | 使用前 | 使用4周后 | 油脂变化率(%) |
实施例3 | 119.67±28.44 | 87.69±19.50 | -26.72 |
实施例4 | 122.05±32.08 | 91.07±20.13 | -25.38 |
实施例5 | 120.32±30.75 | 87.79±21.27 | -27.04 |
实施例6 | 118.80±29.26 | 80.45±18.62 | -32.28 |
对比例1 | 123.77±33.03 | 85.81±18.90 | -30.67 |
对比例2 | 120.48±32.26 | 96.96±19.84 | -19.52 |
对比例3 | 119.54±28.75 | 86.28±20.07 | -27.82 |
对比例4 | 118.26±29.08 | 89.84±20.53 | -24.03 |
对比例5 | 124.17±31.34 | 100.52±19.62 | -19.05 |
结果显示,使用含本发明祛痘除印护肤组合物的祛痘膏能有效减少皮肤油脂分泌,达到很好的控油效果,说明本发明的祛痘除印护肤组合物具良好的控油功效,并以实施例6的效果最佳。
试验例四、祛痘效果试验
选择180名面部有青春痘的受试志愿者作为实验对象,男女各90例,受试志愿者的病症分为:①严重:生痘时间长,数量多,且红肿严重;②轻度:生痘时间不长,数量不多,且红肿不严重或无红肿,180名受试志愿者中,严重的为90例,轻度的为90例,分别将严重患者和轻度患者分为9组,分别为实施例3-6组、对比例1-5组,每组男女比例一致。各试验组每日洁面后,将对应的含本发明实施例3-6、对比例1-5祛痘除印护肤组合物的祛痘膏涂于面部适量,早晚各一次,观察持续使用2周后青春痘去除情况。停用祛痘膏4周后,再观察青春痘的复发情况。
其中,治疗效果判断标准为:改善明显:青春痘90%以上消除,且无痘印,痘坑抚平,皮肤无其他不良反应;效果一般:青春痘30~60%消除,且消除部分痘印,皮肤无其他不良反应;无效果:青春痘0~5%消除,且痘印没有消除,痘坑存在,皮肤无其他不良反应,结果见表5。
表5祛痘测试功效评价表
结果显示,含本发明祛痘除印护肤组合物的祛痘膏具有较佳的祛痘效果,以实施例6的效果最佳,受试志愿者停用祛痘膏4周后没有出现复发现象。表明本发明提供的祛痘除印护肤组合物可有效去除痘痘,消除痘印,抚平痘坑。
以上仅是本发明的优选实施方式,应当指出的是,上述优选实施方式不应视为对本发明的限制,本发明的保护范围应当以权利要求所限定的范围为准。对于本技术领域的普通技术人员来说,在不脱离本发明的精神和范围内,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (9)
1.一种含生长因子的祛痘除印护肤组合物,其特征在于,包括以下重量份的组分:重组人表皮生长因子0.00005~0.001份、水溶性富勒烯3~9份、N-乙酰基-S-法呢基-L-半胱氨酸0.5~3份、夏雪片莲鳞茎提取物1~4份和佛手柑提取物1~4份。
2.根据权利要求1所述的含生长因子的祛痘除印护肤组合物,其特征在于,还包括以下重量份的组分:山茶花提取物1~6份。
3.根据权利要求2所述的含生长因子的祛痘除印护肤组合物,其特征在于,包括以下重量份的组分:重组人表皮生长因子0.0001~0.001份、水溶性富勒烯3~6份、N-乙酰基-S-法呢基-L-半胱氨酸1~2份、夏雪片莲鳞茎提取物1~3份、佛手柑提取物1~2份和山茶花提取物2~4份。
4.根据权利要求3所述的含生长因子的祛痘除印护肤组合物,其特征在于,包括以下重量份的组分:重组人表皮生长因子0.0005份、水溶性富勒烯6份、N-乙酰基-S-法呢基-L-半胱氨酸2份、夏雪片莲鳞茎提取物2份、佛手柑提取物2份和山茶花提取物3份。
5.根据权利要求1-4任一所述的含生长因子的祛痘除印护肤组合物,其特征在于,所述的水溶性富勒烯为硫酸角质素寡聚糖-富勒烯C60复合物,所述的水溶性富勒烯中富勒烯C60所占的质量百分比为4~8%。
6.根据权利要求5所述的含生长因子的祛痘除印护肤组合物,其特征在于,所述的硫酸角质素寡聚糖选自硫酸角质素二糖和硫酸角质素三糖中的至少一种。
7.根据权利要求1-6任一所述的含生长因子的祛痘除印护肤组合物,其特征在于,所述的水溶性富勒烯的制备包括以下步骤:
(1)将硫酸角质素寡聚糖和富勒烯C60粉末按重量比为1:20~30混合均匀,以600~800r/min研磨2~3h,加入双蒸水,置于恒温振荡器,在35~37℃,转速100r/min条件下振荡30min,得混悬液;
(2)将混悬液置于超声水浴锅中,在超声频率为20~30kHz,温度为60℃条件下处理60min,然后采用0.45μm的滤膜进行过滤,将滤液浓缩干燥,即得水溶性富勒烯。
8.权利要求1-7任一所述的含生长因子的祛痘除印护肤组合物在制备祛痘除印护肤品中的应用。
9.一种祛痘除印护肤品,其特征在于,包含权利要求1-7任一所述的含生长因子的祛痘除印护肤组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810658873.XA CN108852927A (zh) | 2018-06-25 | 2018-06-25 | 一种含生长因子的祛痘除印护肤组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810658873.XA CN108852927A (zh) | 2018-06-25 | 2018-06-25 | 一种含生长因子的祛痘除印护肤组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108852927A true CN108852927A (zh) | 2018-11-23 |
Family
ID=64294464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810658873.XA Withdrawn CN108852927A (zh) | 2018-06-25 | 2018-06-25 | 一种含生长因子的祛痘除印护肤组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108852927A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116509782A (zh) * | 2023-05-11 | 2023-08-01 | 百肽德医药生物科技(广东)有限公司 | 净痘因子及其化妆品 |
-
2018
- 2018-06-25 CN CN201810658873.XA patent/CN108852927A/zh not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116509782A (zh) * | 2023-05-11 | 2023-08-01 | 百肽德医药生物科技(广东)有限公司 | 净痘因子及其化妆品 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3326639B1 (en) | Mussel adhesive protein product and applications thereof in suppression of skin inflammations | |
KR101770377B1 (ko) | 여드름 피부개선 화장료 조성물 및 이를 이용한 마스크팩 | |
CN102525864B (zh) | 一种用于祛除青春痘的海洋生物功能化妆品 | |
CN105769698A (zh) | 一种不含防腐剂的化妆品组合物及其应用 | |
CN109431873B (zh) | 一种修复舒缓皮肤炎症的组合物 | |
CN109157450A (zh) | 一种祛痘精华乳 | |
CN105687059A (zh) | 一种用于抗衰老的化妆品组合物及其配制方法、应用 | |
JP2002053428A (ja) | 皮膚外用剤 | |
JP2018522000A (ja) | メラニンに関連する疾患の治療及び予防におけるイガイ接着タンパク質製品の適用 | |
US20110236503A1 (en) | Topical Skincare Composition | |
CN112587446A (zh) | 一种治疗痤疮的组合物及其制备方法和应用 | |
CN106309156A (zh) | 一种阿魏酸去疮水及其制备方法 | |
CN103494737B (zh) | 一种以姜花作为抗衰老护肤因子的化妆品制剂及制备方法 | |
CN108056931A (zh) | 一种祛痘霜及其制备方法 | |
CN115919733A (zh) | 用于祛痘的化妆品组合物及其制备方法 | |
JP2008088075A (ja) | プロフィラグリン/フィラグリン産生促進剤、表皮角化細胞増殖促進剤、表皮/角層正常化用皮膚外用剤、プロフィラグリン及び/又はフィラグリン産生促進方法、及び表皮角化細胞増殖促進方法 | |
CN108852927A (zh) | 一种含生长因子的祛痘除印护肤组合物及其应用 | |
CN105796378A (zh) | 一种祛痘化妆品组合物 | |
CN108354891B (zh) | 一种舒缓乳霜及其制备方法 | |
CN101283956A (zh) | 胆碱酯酶在治疗或改善皮肤症状的皮肤护理用品中的应用 | |
WO2016033899A1 (zh) | 一种调节头皮油脂平衡的去屑组合物 | |
JP2016011283A (ja) | 機能性化粧水 | |
US11260111B2 (en) | Mussel adhesive protein product and applications thereof in suppression of skin inflammations | |
RU2722823C2 (ru) | Косметический состав для лечения и профилактики акне на коже | |
KR20120038699A (ko) | 봉독을 함유하는 여드름 치료 및 예방용 화장 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181123 |
|
WW01 | Invention patent application withdrawn after publication |